RCG Tullahoma is a medicare approved dialysis facility center in Tullahoma, Tennessee and it has 17 dialysis stations. It is located in Coffee county at 1406 North Jackson St., Tullahoma, TN, 37388. You can reach out to the office of RCG Tullahoma at (931) 461-9010. This dialysis clinic is managed and/or owned by Fresenius Medical Care. RCG Tullahoma has the following ownership type - Profit. It was first certified by medicare in December, 1998. The medicare id for this facility is 442624 and it accepts patients under medicare ESRD program.
| Name | RCG Tullahoma |
|---|---|
| Location | 1406 North Jackson St., Tullahoma, Tennessee |
| No. of Dialysis Stations | 17 |
| Medicare ID | 442624 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 1406 North Jackson St., Tullahoma, Tennessee, 37388 | |
| (931) 461-9010 | |
News Archive
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
RCSI is leading an international team of scientists on a major research study that aims to train the next generation of brain cancer researchers.
The American College of Gastroenterology will hold a special briefing for journalists at its 76th Annual Scientific meeting in Washington, DC highlighting new clinical science that explores the role of the "gut microbiota" - the bacterial composition of the GI tract - and the efficacy of probiotics in treating various GI conditions, including antibiotic-associated diarrhea, abdominal discomfort and bloating.
Much as the famed starship Enterprise would deploy a deflector shield to evade enemy attack, tumor cells are capable of switching on a molecular force field of their own to fend off treatments aimed at killing them. Now University of Florida researchers have found a chink in their armor.
Pfizer Inc. and Medivation, Inc. today announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with Alzheimer's disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function.
› Verified 4 days ago
| NPI Number | 1275645095 |
| Organization Name | Dialysis Associates Of Tullahoma |
| Doing Business As | Dialysis Associates Llc |
| Address | 1406 N Jackson St Tullahoma, Tennessee, 37388 |
| Phone Number | (931) 461-9010 |
News Archive
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
RCSI is leading an international team of scientists on a major research study that aims to train the next generation of brain cancer researchers.
The American College of Gastroenterology will hold a special briefing for journalists at its 76th Annual Scientific meeting in Washington, DC highlighting new clinical science that explores the role of the "gut microbiota" - the bacterial composition of the GI tract - and the efficacy of probiotics in treating various GI conditions, including antibiotic-associated diarrhea, abdominal discomfort and bloating.
Much as the famed starship Enterprise would deploy a deflector shield to evade enemy attack, tumor cells are capable of switching on a molecular force field of their own to fend off treatments aimed at killing them. Now University of Florida researchers have found a chink in their armor.
Pfizer Inc. and Medivation, Inc. today announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with Alzheimer's disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function.
› Verified 4 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 59% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 18% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 23% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 57% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 25% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 18% | 14% |
News Archive
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
RCSI is leading an international team of scientists on a major research study that aims to train the next generation of brain cancer researchers.
The American College of Gastroenterology will hold a special briefing for journalists at its 76th Annual Scientific meeting in Washington, DC highlighting new clinical science that explores the role of the "gut microbiota" - the bacterial composition of the GI tract - and the efficacy of probiotics in treating various GI conditions, including antibiotic-associated diarrhea, abdominal discomfort and bloating.
Much as the famed starship Enterprise would deploy a deflector shield to evade enemy attack, tumor cells are capable of switching on a molecular force field of their own to fend off treatments aimed at killing them. Now University of Florida researchers have found a chink in their armor.
Pfizer Inc. and Medivation, Inc. today announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with Alzheimer's disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function.
› Verified 4 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 61% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 21% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 18% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 76% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 14% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 10% | 12% |
News Archive
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
RCSI is leading an international team of scientists on a major research study that aims to train the next generation of brain cancer researchers.
The American College of Gastroenterology will hold a special briefing for journalists at its 76th Annual Scientific meeting in Washington, DC highlighting new clinical science that explores the role of the "gut microbiota" - the bacterial composition of the GI tract - and the efficacy of probiotics in treating various GI conditions, including antibiotic-associated diarrhea, abdominal discomfort and bloating.
Much as the famed starship Enterprise would deploy a deflector shield to evade enemy attack, tumor cells are capable of switching on a molecular force field of their own to fend off treatments aimed at killing them. Now University of Florida researchers have found a chink in their armor.
Pfizer Inc. and Medivation, Inc. today announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with Alzheimer's disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function.
› Verified 4 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 82% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 18% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 75% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 12% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 13% | 12% |
News Archive
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
RCSI is leading an international team of scientists on a major research study that aims to train the next generation of brain cancer researchers.
The American College of Gastroenterology will hold a special briefing for journalists at its 76th Annual Scientific meeting in Washington, DC highlighting new clinical science that explores the role of the "gut microbiota" - the bacterial composition of the GI tract - and the efficacy of probiotics in treating various GI conditions, including antibiotic-associated diarrhea, abdominal discomfort and bloating.
Much as the famed starship Enterprise would deploy a deflector shield to evade enemy attack, tumor cells are capable of switching on a molecular force field of their own to fend off treatments aimed at killing them. Now University of Florida researchers have found a chink in their armor.
Pfizer Inc. and Medivation, Inc. today announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with Alzheimer's disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function.
› Verified 4 days ago
| Dialysis patients with Hemoglobin data | 37 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 16 |
News Archive
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
RCSI is leading an international team of scientists on a major research study that aims to train the next generation of brain cancer researchers.
The American College of Gastroenterology will hold a special briefing for journalists at its 76th Annual Scientific meeting in Washington, DC highlighting new clinical science that explores the role of the "gut microbiota" - the bacterial composition of the GI tract - and the efficacy of probiotics in treating various GI conditions, including antibiotic-associated diarrhea, abdominal discomfort and bloating.
Much as the famed starship Enterprise would deploy a deflector shield to evade enemy attack, tumor cells are capable of switching on a molecular force field of their own to fend off treatments aimed at killing them. Now University of Florida researchers have found a chink in their armor.
Pfizer Inc. and Medivation, Inc. today announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with Alzheimer's disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function.
› Verified 4 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 55 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 529 |
| Percentage of adult patients getting regular hemodialysis at the center | 99 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
RCSI is leading an international team of scientists on a major research study that aims to train the next generation of brain cancer researchers.
The American College of Gastroenterology will hold a special briefing for journalists at its 76th Annual Scientific meeting in Washington, DC highlighting new clinical science that explores the role of the "gut microbiota" - the bacterial composition of the GI tract - and the efficacy of probiotics in treating various GI conditions, including antibiotic-associated diarrhea, abdominal discomfort and bloating.
Much as the famed starship Enterprise would deploy a deflector shield to evade enemy attack, tumor cells are capable of switching on a molecular force field of their own to fend off treatments aimed at killing them. Now University of Florida researchers have found a chink in their armor.
Pfizer Inc. and Medivation, Inc. today announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with Alzheimer's disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function.
› Verified 4 days ago
| Adult patients getting regular peritoneal dialysis at the center | 23 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 171 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 94 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
RCSI is leading an international team of scientists on a major research study that aims to train the next generation of brain cancer researchers.
The American College of Gastroenterology will hold a special briefing for journalists at its 76th Annual Scientific meeting in Washington, DC highlighting new clinical science that explores the role of the "gut microbiota" - the bacterial composition of the GI tract - and the efficacy of probiotics in treating various GI conditions, including antibiotic-associated diarrhea, abdominal discomfort and bloating.
Much as the famed starship Enterprise would deploy a deflector shield to evade enemy attack, tumor cells are capable of switching on a molecular force field of their own to fend off treatments aimed at killing them. Now University of Florida researchers have found a chink in their armor.
Pfizer Inc. and Medivation, Inc. today announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with Alzheimer's disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function.
› Verified 4 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at RCG Tullahoma with elevated calcium levels.
| Patients with hypercalcemia | 82 |
| Hypercalcemia patient months | 717 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 86 |
| Patients with Serumphosphor less than 3.5 mg/dL | 11 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 30 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 37 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 14 |
| Patients with Serumphosphor greater than 7 mg/dL | 8 |
News Archive
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
RCSI is leading an international team of scientists on a major research study that aims to train the next generation of brain cancer researchers.
The American College of Gastroenterology will hold a special briefing for journalists at its 76th Annual Scientific meeting in Washington, DC highlighting new clinical science that explores the role of the "gut microbiota" - the bacterial composition of the GI tract - and the efficacy of probiotics in treating various GI conditions, including antibiotic-associated diarrhea, abdominal discomfort and bloating.
Much as the famed starship Enterprise would deploy a deflector shield to evade enemy attack, tumor cells are capable of switching on a molecular force field of their own to fend off treatments aimed at killing them. Now University of Florida researchers have found a chink in their armor.
Pfizer Inc. and Medivation, Inc. today announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with Alzheimer's disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function.
› Verified 4 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 62 |
| Patient months included in arterial venous fistula and catheter summaries | 466 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 74 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 3 |
News Archive
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
RCSI is leading an international team of scientists on a major research study that aims to train the next generation of brain cancer researchers.
The American College of Gastroenterology will hold a special briefing for journalists at its 76th Annual Scientific meeting in Washington, DC highlighting new clinical science that explores the role of the "gut microbiota" - the bacterial composition of the GI tract - and the efficacy of probiotics in treating various GI conditions, including antibiotic-associated diarrhea, abdominal discomfort and bloating.
Much as the famed starship Enterprise would deploy a deflector shield to evade enemy attack, tumor cells are capable of switching on a molecular force field of their own to fend off treatments aimed at killing them. Now University of Florida researchers have found a chink in their armor.
Pfizer Inc. and Medivation, Inc. today announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with Alzheimer's disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function.
› Verified 4 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 70 |
| Hospitalization Rate in facility | 201.3 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 334.5 |
| Hospitalization Rate: Lower Confidence Limit | 124.5 |
News Archive
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
RCSI is leading an international team of scientists on a major research study that aims to train the next generation of brain cancer researchers.
The American College of Gastroenterology will hold a special briefing for journalists at its 76th Annual Scientific meeting in Washington, DC highlighting new clinical science that explores the role of the "gut microbiota" - the bacterial composition of the GI tract - and the efficacy of probiotics in treating various GI conditions, including antibiotic-associated diarrhea, abdominal discomfort and bloating.
Much as the famed starship Enterprise would deploy a deflector shield to evade enemy attack, tumor cells are capable of switching on a molecular force field of their own to fend off treatments aimed at killing them. Now University of Florida researchers have found a chink in their armor.
Pfizer Inc. and Medivation, Inc. today announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with Alzheimer's disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function.
› Verified 4 days ago
The rate of readmission show you whether patients who were being treated regularly at RCG Tullahoma were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 25.2 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 34.8 |
| Readmission Rate: Lower Confidence Limit | 17.1 |
News Archive
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
RCSI is leading an international team of scientists on a major research study that aims to train the next generation of brain cancer researchers.
The American College of Gastroenterology will hold a special briefing for journalists at its 76th Annual Scientific meeting in Washington, DC highlighting new clinical science that explores the role of the "gut microbiota" - the bacterial composition of the GI tract - and the efficacy of probiotics in treating various GI conditions, including antibiotic-associated diarrhea, abdominal discomfort and bloating.
Much as the famed starship Enterprise would deploy a deflector shield to evade enemy attack, tumor cells are capable of switching on a molecular force field of their own to fend off treatments aimed at killing them. Now University of Florida researchers have found a chink in their armor.
Pfizer Inc. and Medivation, Inc. today announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with Alzheimer's disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function.
› Verified 4 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at RCG Tullahoma get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .6 (As Expected) |
| SIR: Upper Confidence Limit | 1.98 |
| SIR: Lower Confidence Limit | .1 |
News Archive
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
RCSI is leading an international team of scientists on a major research study that aims to train the next generation of brain cancer researchers.
The American College of Gastroenterology will hold a special briefing for journalists at its 76th Annual Scientific meeting in Washington, DC highlighting new clinical science that explores the role of the "gut microbiota" - the bacterial composition of the GI tract - and the efficacy of probiotics in treating various GI conditions, including antibiotic-associated diarrhea, abdominal discomfort and bloating.
Much as the famed starship Enterprise would deploy a deflector shield to evade enemy attack, tumor cells are capable of switching on a molecular force field of their own to fend off treatments aimed at killing them. Now University of Florida researchers have found a chink in their armor.
Pfizer Inc. and Medivation, Inc. today announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with Alzheimer's disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function.
› Verified 4 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether RCG Tullahoma's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 61 |
| Transfusion Rate in facility | 56.2 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 119.3 |
| Transfusion Rate: Lower Confidence Limit | 29 |
News Archive
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
RCSI is leading an international team of scientists on a major research study that aims to train the next generation of brain cancer researchers.
The American College of Gastroenterology will hold a special briefing for journalists at its 76th Annual Scientific meeting in Washington, DC highlighting new clinical science that explores the role of the "gut microbiota" - the bacterial composition of the GI tract - and the efficacy of probiotics in treating various GI conditions, including antibiotic-associated diarrhea, abdominal discomfort and bloating.
Much as the famed starship Enterprise would deploy a deflector shield to evade enemy attack, tumor cells are capable of switching on a molecular force field of their own to fend off treatments aimed at killing them. Now University of Florida researchers have found a chink in their armor.
Pfizer Inc. and Medivation, Inc. today announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with Alzheimer's disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function.
› Verified 4 days ago
The rate of mortality show you whether patients who were being treated regularly at RCG Tullahoma lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 331 |
| Mortality Rate in facility | 16.7 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 22 |
| Mortality Rate: Lower Confidence Limit | 12.4 |
News Archive
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
RCSI is leading an international team of scientists on a major research study that aims to train the next generation of brain cancer researchers.
The American College of Gastroenterology will hold a special briefing for journalists at its 76th Annual Scientific meeting in Washington, DC highlighting new clinical science that explores the role of the "gut microbiota" - the bacterial composition of the GI tract - and the efficacy of probiotics in treating various GI conditions, including antibiotic-associated diarrhea, abdominal discomfort and bloating.
Much as the famed starship Enterprise would deploy a deflector shield to evade enemy attack, tumor cells are capable of switching on a molecular force field of their own to fend off treatments aimed at killing them. Now University of Florida researchers have found a chink in their armor.
Pfizer Inc. and Medivation, Inc. today announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with Alzheimer's disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function.
› Verified 4 days ago
News Archive
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.
RCSI is leading an international team of scientists on a major research study that aims to train the next generation of brain cancer researchers.
The American College of Gastroenterology will hold a special briefing for journalists at its 76th Annual Scientific meeting in Washington, DC highlighting new clinical science that explores the role of the "gut microbiota" - the bacterial composition of the GI tract - and the efficacy of probiotics in treating various GI conditions, including antibiotic-associated diarrhea, abdominal discomfort and bloating.
Much as the famed starship Enterprise would deploy a deflector shield to evade enemy attack, tumor cells are capable of switching on a molecular force field of their own to fend off treatments aimed at killing them. Now University of Florida researchers have found a chink in their armor.
Pfizer Inc. and Medivation, Inc. today announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with Alzheimer's disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function.
› Verified 4 days ago